Methamphetamine-Related Disorders

Härtel-Petri, Roland; Hamdorf, Willem; Havemann-Reinecke, Ursula; Mühlig, Stephan; Wodarz, Norbert

doi:10.3238/arztebl.2017.0455

Cited by 18 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methamphetamine abuse also seems to be prevalent in specific populations such as groups of gay men, mainly in London, who participate in so-called 'slamming' or 'chem-sex' parties. Sexual intercourse under the influence of drugs is associated with an intravenous use of the drug, where the injecting equipment is often shared, and the use of a cocktail of drugs like mephedrone and gamma-hydroxybutyrate (GHB) (9,10). Although the extent of this type of drug use remains unclear, drug services in London have reported increasing demand for treatment linked to problems associated with methamphetamine use by gay men (3).…”

Section: Risk Groups For Methamphetamine Usementioning

confidence: 99%

“…Beyond contingency management and cognitive behavioral therapy, guidelines also reported that psychoeducation, motivational interviewing, m o t i v a t i o n e n h a n c e m e n t , a c c e p t a n c e a n d commitment therapy, Matrix model (cognitive behavioral therapy with family education and selfhelp participation) and FAST (Family Alternative Treatment Activities, Self-Help and Therapeutic Community), stepped-care approaches (a need-based, incremental system of interventions, ranging from low-threshold educative approaches to complex inpatient treatment methods) and community-based treatments were efficient approaches for methamphetamine-use disorder (9). It is recommended that patients be offered at least one full year of further follow-up care to prevent relapse (9).…”

Section: Psychotherapeutic Interventions For Methamphetamine Use Disomentioning

confidence: 99%

“…Any person who uses methamphetamine, with or without a diagnosis of methamphetamine-use disorder, should be offered psychotherapeutic counseling or treatment of an appropriate type for his or her individual needs and motivation (9). Cognitive behavioral approaches, be they in conjunction with pharmacotherapy or not, have been shown to increase treatment attendance and to reduce methamphetamine use and risky sexual behavior (60)(61)(62).…”

Section: Psychotherapeutic Interventions For Methamphetamine Use Disomentioning

confidence: 99%

“…If the patient needs treatment for marked agitation, aggressiveness, or psychotic symptoms, benzodiazepines should be used as the agent of first choice. If benzodiazepines are not sufficient to sedate the patient, adding an antipsychotic drug may be considered, especially if the patient has delusions or hallucinations (9). Patients with methamphetamine-use disorder should be offered a course of qualified withdrawal treatment for a minimum of three weeks, and acute treatment may also be combined with the use of other psychotherapeutic methods, such as behavioral therapy or contingency management as soon as possible (9).…”

Section: Acute Treatment For Methamphetamine Intoxicationmentioning

confidence: 99%

“…The drugs studied for methamphetamine-use disorder include acetylcysteine, antidepressants, antiepileptic drugs, atypical antipsychotic drugs, calcium antagonists, muscle relaxants, opioid antagonists, psychostimulants, and varenicline (9). Methamphetamine-related persistent or comorbid syndromes such as methamphetamineassociated psychosis, depressive syndromes, anxiety, and sleep disorders are usually treated in a symptomoriented manner (57).…”

Section: Pharmacotherapy For Methamphetamine Use Disordermentioning

confidence: 99%

See 4 more Smart Citations

Update on methamphetamine: an old problem that we have recently encountered

Evren¹,

Bozkurt²

2018

Dusunen Adam

View full text Add to dashboard Cite

Section: Risk Groups For Methamphetamine Usementioning

confidence: 99%

Section: Psychotherapeutic Interventions For Methamphetamine Use Disomentioning

confidence: 99%

Section: Psychotherapeutic Interventions For Methamphetamine Use Disomentioning

confidence: 99%

Section: Acute Treatment For Methamphetamine Intoxicationmentioning

confidence: 99%

Section: Pharmacotherapy For Methamphetamine Use Disordermentioning

confidence: 99%

See 3 more Smart Citations

Update on methamphetamine: an old problem that we have recently encountered

Evren¹,

Bozkurt²

2018

Dusunen Adam

View full text Add to dashboard Cite

Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder

2020

View full text Add to dashboard Cite

In the wake of the opioid crisis, methamphetamine has reemerged as a challenge to mental health clinicians and researchers alike. Methamphetamine is now available in different forms such as ice, powder, and pills, with different pharmacokinetic characteristics that make them popular among certain types of individuals. 1 Recent seizure data suggest that methamphetamine production and trafficking are spreading into new areas of the globe. 2 According to the Automation of Reports and Consolidated Orders System, methamphetamine consumption increased 4-fold between 2015 and 2016 and total stimulant use doubled in the last decade. 3 From 2011 through 2016, the age-adjusted rate of drug overdose deaths involving methamphetamine more than tripled. 4 Moreover, drug overdose deaths involving cocaine, amphetamines, or both substances combined increased 42.4% from 12 122 in 2015 to 17 258 in 2016. 5 Based on the most recent data from the National Survey on Drug Use and Health, 6 the 12-month prevalence of individuals aged 12 years or older reporting methamphetamine use has increased by 195% from its low in 2010 to 2018 (Figure 1), and it is estimated that 1.86 million Americans used methamphetamine in 2018. These numbers underline the importance of paying attention to the possibility of the next substance use crisis. However, whereas opioid use disorder can be treated pharmacologically 7 and behaviorally, 8 there are significant challenges for the treatment of methamphetamine use disorder (MUD). This review focuses on 3 specific aspects of MUD. First, the neurobiology of methamphetamine is more complex than the traditional view of it as a monoaminergic modulator. Second, the clinical presentation is not limited to the symptoms associated with use disorder but extend to medical presentations, most notably the cardiovascular and cerebrovascular systems. Third, pharmacologic interventions focused on modulating the monoaminergic pathways have largely failed, and new pharmacologic approaches are necessary to focus on novel treatment targets. In the final section, several suggestions will be proposed for both clinicians and researchers to advance the understanding of MUD. Biological Pathways, Neural Basis, and CognitionMethamphetamine has been conceptualized primarily as a releaser of dopamine, serotonin, noradrenaline, and adrenaline from nerve terminals in the central and peripheral nervous system, 9 which occurs via several different mechanisms, including (1) redistributing catecholamines from synaptic vesicles to the cytosol, (2) reversing the plasma membrane transport of neurotransmitters, (3) blocking the activity of monoamine transporters, (4) decreasing the expression of dopamine transporters at the cell surface, (5) inhibiting monoamine oxidase activity, and (6) increasing the activity and IMPORTANCE The prevalence of and mortality associated with methamphetamine use has doubled during the past 10 years. There is evidence suggesting that methamphetamine use disorder could be the next substance use crisis in the United ...

show abstract

Functional connectivity abnormalities underlying mood disturbances in male abstinent methamphetamine abusers

Jiang

Sun

Zhou

et al. 2021

Human Brain Mapping

View full text Add to dashboard Cite

Anxiety and depression are the most common withdrawal symptoms of methamphetamine (METH) abuse, which further exacerbate relapse of METH abuse. To date, no effective pharmacotherapy exists for METH abuse and its withdrawal symptoms.Therefore, understanding the neuromechanism underlying METH abuse and its withdrawal symptoms is essential for developing clinical strategies and improving patient care. The aims of this study were to investigate brain network abnormalities in METH abusers (MAs) and their associations with affective symptoms. Forty-eight male abstinent MAs and 48 age-gender matched healthy controls were recruited and underwent resting state functional magnetic resonance imaging (fMRI). The severity of patient anxiety and depressive symptoms were measured by Hamilton anxiety and depression rating scales, which decreased across the duration of abstinence. Independent component analysis was used to investigate the brain network functional connectivity (FC) properties. Compared with healthy controls, MAs demonstrated hypo-intra-network FC in the cerebellar network and hyper-intra-network FC in the posterior salience network. A whole-brain regression analysis revealed that FC strength of clusters located in the right rostral anterior cingulate cortex (rACC) within the ventromedial network (VMN) was associated with affective symptoms in the patients. Importantly, the intra-network FC strength of the rACC in VMN mediated the association between abstinence duration and the severity level of affective symptoms. Our results demonstrate alterations in brain functional networks underlying Jing Li, Keith Kendrick, and Qiyong Gong contributed equally to the study.

show abstract

Methamphetamine-Related Disorders

Cited by 18 publications

References 17 publications

Update on methamphetamine: an old problem that we have recently encountered

Update on methamphetamine: an old problem that we have recently encountered

Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder

Functional connectivity abnormalities underlying mood disturbances in male abstinent methamphetamine abusers

Contact Info

Product

Resources

About